Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388496 | 0.85 | ADORA2A (0.58) | ADORA2ALRRK2CSNK1DGSK3BAOC3 | |
| SCHEMBL5373387 | 0.84 | NTRK1 (0.44) | LRRK2CSNK1DNTRK1GSK3BMAPK1 | |
| SCHEMBL8435451 | 0.84 | CSNK1D (0.47) | ADORA2ALRRK2CSNK1DNTRK1MAPK1 | |
| SCHEMBL5398587 | 0.81 | MAP2K4 (0.51) | ADORA2ALRRK2CSNK1DNTRK1GSK3B | |
| SCHEMBL5378119 | 0.80 | CSNK1D (0.54) | ADORA2ALRRK2CSNK1DNTRK1MAPK1 | |
| SCHEMBL5387177 | 0.79 | CSNK1D (0.67) | ADORA2ACSNK1DNTRK1MAPK1AOC3 | |
| SCHEMBL5378626 | 0.78 | CSNK1D (0.48) | ADORA2ALRRK2CSNK1DNTRK1MAPK1 | |
| SCHEMBL5387116 | 0.78 | CSNK1D (0.54) | ADORA2ACSNK1DNTRK1GSK3B | |
| SCHEMBL5378629 | 0.78 | CSNK1D (0.46) | ADORA2ACSNK1DNTRK1GSK3BMAPK1 | |
| SCHEMBL5380485 | 0.78 | CSNK1D (0.53) | ADORA2ACSNK1DNTRK1MAPK1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | ADORA2A 2524/4885LRRK2 231/4885CSNK1D 349/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | ADORA2A 1854/4885LRRK2 1898/4885CSNK1D 1173/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | ADORA2A 2097/4885LRRK2 280/4885CSNK1D 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.